Cargando…

Expanded Haemodialysis as a Current Strategy to Remove Uremic Toxins

Chronic kidney disease (CKD) is characterized by the retention of solutes named uremic toxins, which strongly associate with high morbidity and mortality. Mounting evidence suggests that targeting uremic toxins and/or their pathways may decrease the risk of cardiovascular disease in CKD patients. Di...

Descripción completa

Detalles Bibliográficos
Autores principales: Ciceri, Paola, Cozzolino, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8226798/
https://www.ncbi.nlm.nih.gov/pubmed/34073439
http://dx.doi.org/10.3390/toxins13060380
_version_ 1783712372771258368
author Ciceri, Paola
Cozzolino, Mario
author_facet Ciceri, Paola
Cozzolino, Mario
author_sort Ciceri, Paola
collection PubMed
description Chronic kidney disease (CKD) is characterized by the retention of solutes named uremic toxins, which strongly associate with high morbidity and mortality. Mounting evidence suggests that targeting uremic toxins and/or their pathways may decrease the risk of cardiovascular disease in CKD patients. Dialysis therapies have been developed to improve removal of uremic toxins. Advances in our understanding of uremic retention solutes as well as improvements in dialysis membranes and techniques (HDx, Expanded Hemodialysis) will offer the opportunity to ameliorate clinical symptoms and outcomes, facilitate personalized and targeted dialysis treatment, and improve quality of life, morbidity and mortality.
format Online
Article
Text
id pubmed-8226798
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82267982021-06-26 Expanded Haemodialysis as a Current Strategy to Remove Uremic Toxins Ciceri, Paola Cozzolino, Mario Toxins (Basel) Review Chronic kidney disease (CKD) is characterized by the retention of solutes named uremic toxins, which strongly associate with high morbidity and mortality. Mounting evidence suggests that targeting uremic toxins and/or their pathways may decrease the risk of cardiovascular disease in CKD patients. Dialysis therapies have been developed to improve removal of uremic toxins. Advances in our understanding of uremic retention solutes as well as improvements in dialysis membranes and techniques (HDx, Expanded Hemodialysis) will offer the opportunity to ameliorate clinical symptoms and outcomes, facilitate personalized and targeted dialysis treatment, and improve quality of life, morbidity and mortality. MDPI 2021-05-26 /pmc/articles/PMC8226798/ /pubmed/34073439 http://dx.doi.org/10.3390/toxins13060380 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Ciceri, Paola
Cozzolino, Mario
Expanded Haemodialysis as a Current Strategy to Remove Uremic Toxins
title Expanded Haemodialysis as a Current Strategy to Remove Uremic Toxins
title_full Expanded Haemodialysis as a Current Strategy to Remove Uremic Toxins
title_fullStr Expanded Haemodialysis as a Current Strategy to Remove Uremic Toxins
title_full_unstemmed Expanded Haemodialysis as a Current Strategy to Remove Uremic Toxins
title_short Expanded Haemodialysis as a Current Strategy to Remove Uremic Toxins
title_sort expanded haemodialysis as a current strategy to remove uremic toxins
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8226798/
https://www.ncbi.nlm.nih.gov/pubmed/34073439
http://dx.doi.org/10.3390/toxins13060380
work_keys_str_mv AT ciceripaola expandedhaemodialysisasacurrentstrategytoremoveuremictoxins
AT cozzolinomario expandedhaemodialysisasacurrentstrategytoremoveuremictoxins